Belite Bio, Inc

NASDAQ:BLTE

Biotechnology

Healthcare
$151.02 +0.31%

+$0.46 today

Market cap
$6.08B
Beta
-1.24
P/E (TTM)
-65.9
EPS (TTM)
-$2.26
52W Low $56.10High $200.00

Volume 0.14M

Average 0.17M

Returns on capital

Belite Bio, Inc management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-10.1%

avg 7.6%

ROIC

-10.9%

avg -30.8%

ROA

-9.9%

avg -28.5%

Analysis

ROA is currently the strongest return metric at -9.9% versus its period average of -28.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Kelly Kilpatrick

Chief Commercial Officer————

Hendrik Scholl

Chief Medical Officer—57——

Nathan L. Mata

Chief Scientific Officer—600<0.01%

Yu-Hsin Lin

Chairman of the Board of Directors & Chief Executive Officer—48187.95K0.47%

Hao-Yuan Chuang

Chief Financial Officer & Director—42180.26K0.45%

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

175

$40.63M

Net Transaction Value

−$40.63M

Net selling

Most Active

MATA NATHAN L.

103 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$4K
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$19.9K
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$8.3K
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$32.7K
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$2.4K
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$340
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$13.1K
Oct 1, 26

Scholl Hendrik Peter

Indirect

Sell$2K
Sep 8, 26

Chuang Hao-Yuan

Direct

Sell$507.4K
Sep 8, 26

Lin Yu-Hsin

Direct

Sell$1.7M

1–10 of 175

Summary

Insiders reported 0 buys worth $0.00 and 175 sells worth $40.63M over the last 12 months. That adds up to net selling of $40.63M. MATA NATHAN L. was the most active insider with 103 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Belite Bio, Inc compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BLTE's management, answered from reported figures.

Who manages BLTE?

Belite Bio, Inc (BLTE) lists 5 active executives. The top listed executive is Kelly Kilpatrick, Chief Commercial Officer.

Are BLTE insiders buying or selling?

Recent insider activity shows net selling of $38.82M.